The American Journal of Surgery: Introduction

American Journal of Surgery

Volumn 186, Issue 5 SUPPL. 1, 2003, Pages

  Itani, Kamal M F ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; METICILLIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DRUG CHOICE; DRUG COST; DRUG SAFETY; DRUG USE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MULTIDRUG RESISTANCE; MYCOSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SEPSIS; SURGICAL PATIENT;

EID: 0347479314     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2003.10.001     Document Type: Conference Paper

References (32)

1. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate anti-microbial treatment of infections a risk factor for hospital mortality among critically ill patients . Chest. 115:1999;462-474.
2. Heizelman M., Scott M., Lam T. Factors predisposing to bacterial invasion and infection. Am J Surg. 183:2002;179-190.
3. Polk H.C. Pharmacoeconomics for surgeons [editorial]. Am J Surg. 183:2002;1.
4. Wunderink R.G. Pharmacoeconomics of pneumonia. Am J Surg. 179:(suppl 1):2000;51-57.
5. English W.P., Williams M.D. Should aminoglycoside antibiotics be abandoned? Am J Surg. 180:2000;512-515.
6. Elliott D., Kufera J.A., Myers R.A. The microbiology of necrotizing soft tissue infections. Am J Surg. 179:2000;361-366.
7. Spain D.A. Pneumonia in the surgical patient duration of therapy and does the organism matter? Am J Surg. 179:(suppl 1):2000;36-39.
8. National Nosocomial Infections Surveillance (NNIS) System report data summary from January 1990-May 1999; issued June 1999. Am J Infect Control 1999;27:520-532.
9. Edmond M.B., Wallace S.E., McClesh D.K., et al. Nosocomial bloodstream infections in the United States hospital a three-year analysis . Clin Infect Dis. 29:1999;239-244.
10. Crove M., Isphahani P., Humphreys H., et al. Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK 1985-1996. Eur J Clin Microbiol Infect Dis. 17:1998;377-384.
11. Pfaller M.A., Jones R.N., Doern G.V., et al. Survey of blood stream infections attributable to gram-positive cocci frequency of occurrence and anti-microbial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Anti-microbial Surveillance Program. SENTRY Participants Group . Diagn Microbiol Infect Dis. 33:1999;283-297.
12. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 348:2003;1546-1554.
13. Thornsberry C. NNIS, 38th Interscience Conference on Anti-microbial Agents and Chemotherapy; September 24-27, 1998; San Diego, CA. Abstract E22.
14. Hiramatsu K., Aritaka N., Hanoki H., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1997;1670-1673.
15. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997 [published erratum appears in MMWR Morbid Mortal Wkly Rep 1997;46:851]. MMWR Morb Mortal Wkly Rep 1997;46:813-815.
16. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567.
17. Charlebois E.D., Bangsberg D.R., Moss N., et al. Population based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis. 34:2002;425-433.
18. Klein N.C., Cuhna B.A. New uses of older antibiotics. Med Clin North Am. 85:2001;125-132.
19. Watanakunakom C. Clindamycin therapy of Staphylococcus aureus endocarditis clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin . Am J Med. 60:1976;419-425.
20. Allington D.R., Rivey M.P. Quinupristin/dalfopristin a therapeutic review . Clin Ther. 23:2001;24-44.
21. Linden P. Use of linezolid for gram-positive infections. Infect Med. 19:2002;25-32.
22. Fuchs P.C., Barry A.L., Brown S.D. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother. 49:2002;467-470.
23. Bharmani S.M., Ballow C.H. New agents for gram-positive bacteria. Curr Opin Microbiol. 3:2000;528-534.
24. Itokazu G.S., Quinn J.P., Bell-Dixon C., et al. Anti-microbial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units evaluation of a national postmarketing surveillance program . Clin Infect Dis. 23:1996;779-789.
25. Newhauser M.M., Weinstein R.A., Rydman R., et al. Antibiotic resistance among gram-negative bacilli in US intensive care units - implications for fluoroquinolone use. JAMA. 289:2003;885-888.
26. Tankovic J., Bachoual R., Ouabdesselam S., et al. In vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram negative bacilli and Enterococcus faecalis. J Antimicrob Chemother. 43:(suppl B):1999;S19-S23.
27. Beck-Sague C.M., Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 167:1993;1247-1251.
28. Lombardi D.P., Engleberg N.C. Anaerobic bacteremia incidence, patient characteristics, and clinical significance . Am J Med. 92:1992;53-60.
29. Solonen J.H., Eerola E., Meusman O. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis. 26:1998;1413-1417.
30. Goldstein J. Anaerobic bacteremia. Clin Infect Dis. 23:(suppl 1):1996;S97-S101.
31. Brook I. Anaerobic bacterial bacteremia 12-year experience in two military hospitals . J Infect Dis. 160:1990;1071-1075.
32. Snydman D.R., Jacobus N.V., McDermott L.A., et al. National Survey on the Susceptibility of Bacteroides fragilis Group report and analysis of trends for 1997-2000 . Clin Infect Dis. 35:(suppl 1):2002;S126-S134.